Introduction
============

It is well known that the mutations of *EGFR* act as one of the most frequent driver genes in non-small cell lung cancer (NSCLC) patients, especially among East Asian female lung adenocarcinoma patients.[@b1-ott-10-3399],[@b2-ott-10-3399] Previous studies have shown that *EGFR*-tyrosine kinase inhibitors (*EGFR*-TKIs) could achieve a high response rate and yield a promising efficacy for *EGFR* mutants.[@b3-ott-10-3399]--[@b6-ott-10-3399]

Despite a response rate of 60%--70% in *EGFR*-mutated lung cancer patients treated with *EGFR*-TKIs, 10%--20% of individuals developed primary resistance.[@b4-ott-10-3399]--[@b6-ott-10-3399] The mechanism is currently ill defined. Possible contributing factors included T790M mutation, *MET* amplification and *PIK3CA* mutation.[@b7-ott-10-3399]--[@b9-ott-10-3399] Concomitant genetic alterations were found to be associated with primary resistance in *EGFR*-mutated NSCLC patients.[@b10-ott-10-3399],[@b11-ott-10-3399] However, the studies were somewhat limited, and only several case series were reported. Furthermore, the efficacies of *EGFR*-TKIs have remained elusive.

Here, *ALK* and *ROS1* fusion gene panel was used for screening the patients har-boring *EGFR*-mutated samples and further detecting the therapeutic efficacies of *EGFR*-TKIs.

Materials and methods
=====================

Patient samples
---------------

Consecutive *EGFR*-mutated patients receiving *EGFR*-TKIs for lung adenocarcinoma were screened at Hangzhou Cancer Hospital between 2009 and 2015. The inclusion criteria were as follows: 1) uses of *EGFR*-TKIs during advanced stage; 2) sufficient residual tissues for detecting *ALK* and *ROS1* fusion genes and 3) confirmed as having sensitive *EGFR* mutation. Resistant mutations such as *T790M*, *S768I* and exon 20 insertions were excluded. The study protocol was approved by the ethics committee of Hangzhou Cancer Hospital, and written informed consents were obtained from all patients.

Detection of *EGFR/ALK/ROS1* fusion gene
----------------------------------------

*EGFR* gene was detected by amplification refractory mutation system (ARMS)-based kit (Amoy, Xiamen, China). It was capable of detecting the following 23 mutations: three in exon 18 (G719A, G719C and G719S), 13 deletions in exon 19, two mutations in exon 20 (T790M and S768I), three insertions in exon 20 and two mutations in exon 21 (L858R and L861Q).

The *ALK* and *ROS1* fusion mRNAs were detected by polymerase chain reaction (PCR) using fusion gene detection kit (Amoy). Briefly, total RNA was extracted using Qiagen (Dusseldorf, Germany) RNeasy FFPE kit. mRNA was reverse transcribed into cDNA for 1 h at 42°C. β-actin was used as an internal control. The conditions of reverse transcription-polymerase chain reaction (RT-PCR) were as follows: initial denaturation at 95°C for 5 min, followed by 95°C for 25 s, 64°C for 20 s and 72°C for 20 s for ensuring specificity and 31 cycles at 93°C for 25 s, 60°C for 35 s and 72°C for 20 s. Data collection and sensitivity analysis were detailed previously.[@b12-ott-10-3399] The subtypes of *EGFR/ALK/ROS1* genes are summarized in [Table S1](#SD1-ott-10-3399){ref-type="supplementary-material"}.

Evaluations of TKI treatment
----------------------------

Tumors were evaluated during the treatment with *EGFR*-TKIs or *ALK/ROS1* inhibitor every 8 weeks. Objective tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Objective response rate (ORR) included complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD).

Statistical analyses
--------------------

The Kaplan--Meier method was used for survival analysis. Progression-free survival (PFS) of TKIs was defined as the time from initiating TKI treatment to documented progression or mortality from any cause. Statistical analysis was performed using the SPSS 18 software (SPSS Inc., Chicago, IL, USA). The median follow-up period was 28.5 months (4.5--65 months). The last follow-up time was October 31, 2016.

Results
=======

Patient characteristics
-----------------------

A total of 421 patients were enrolled, and their clinical characteristics are summarized in [Table 1](#t1-ott-10-3399){ref-type="table"}. Among the patients, 13 were confirmed as having concomitant *ALK*/*ROS1* fusion gene. Their clinical characteristics are summarized in [Table 2](#t2-ott-10-3399){ref-type="table"}. There were six males and seven females with a median age of 55 years. One patient was a former smoker and 12 had never smoked. The comparisons of single *EGFR* versus concomitant gene mutations are listed in [Table 1](#t1-ott-10-3399){ref-type="table"}.

Gene profiles
-------------

The genetic details of 421 *EGFR* mutations are as follows: exon 19 deletions (n=217), L858R mutation in exon 21 (n=169), G719X in exon 18 (n=21) and L861Q (n=14). Concomitant gene fusions were identified in 13 patients (3.1%), including *ALK* (n=10, 2.4%) and *ROS1* (n=3, 0.7%). Their profiles are detailed in [Table 2](#t2-ott-10-3399){ref-type="table"}.

Efficacy of TKIs
----------------

All 421 patients received *EGFR*-TKIs. Among 13 patients with concomitant genes, eight switched to crizotinib after ineffective *EGFR*-TKIs. The agents of *EGFR*-TKIs included erlotinib (n=71), gefitinib (n=126) and icotinib (n=224). None of them received any second-generation *EGFR*-TKI since so far none have been approved in China.

The clinical efficacies of 408 single *EGFR*-mutated patients included CR (n=2, 0.5%), PR (n=249, 61.0%), SD (n=87, 21.3%) and PD (n=70, 17.2%). In concomitant *ALK*/*ROS1* mutants, the outcomes of *EGFR*-TKIs were PR (n=6), SD (n=3) and PD (n=4). The efficacy comparisons between single *EGFR* and concomitant gene mutations are shown in [Table 3](#t3-ott-10-3399){ref-type="table"}.

The overall value of PFS was 10.7 months (95% CI, 10.0--11.4). The median values of PFS were 10.7 and 6.6 months in mutants of single *EGFR* and concomitant *ALK*/*ROS1* fusion gene, respectively ([Figure 1, *P*](#f1-ott-10-3399){ref-type="fig"}=0.004). For eight patients on crizotinib, the value of PFS was 6.0 months for concomitant *ALK*/*ROS1* fusion gene mutations (95% CI, 3.2--8.8).

The overall median value of OS was 21.0 months (95% CI, 18.9--23.4). No survival difference existed between single *EGFR* mutants and those with concomitant *ALK*/*ROS1* fusion gene mutations (21.0 vs 23.0 months, *P*=0.196; [Figure 2](#f2-ott-10-3399){ref-type="fig"}).

Discussion
==========

Our results showed that 3.1% of *EGFR*-mutated lung adeno-carcinoma Chinese patients harbored *ALK/ROS1* fusion genes. Concurrent *ALK/ROS1* gene decreased the therapeutic efficacy of *EGFR*-TKIs. However, it had no impact on the overall survival (OS).

Although gene alterations were presumably mutually exclusive in lung adenocarcinoma,[@b13-ott-10-3399] some reports revealed that genes might occur concomitantly.[@b14-ott-10-3399],[@b15-ott-10-3399] With the emerging of high-throughput sequencing, many concomitant genes have been detected. The frequency of concomitant *EGFR/ALK* or *EGFR/ROS1* mutations was 3.1% in the present study, and this figure was consistent with previous reports.[@b16-ott-10-3399]--[@b19-ott-10-3399]

Owing to a low frequency of concomitant genes in *EGFR*-mutated lung cancer patients, the efficacy of *EGFR*-TKIs is largely unknown. The median PFS of first-generation *EGFR*-TKIs was 11.2 months in patients harboring concomitant *EGFR/ALK* genes in one report by Yang et al.[@b20-ott-10-3399] For concomitant *ALK/ROS1* and *EGFR* mutants, there was a practical dilemma of therapeutic sequence of *EGFR*-TKIs and *ALK/ROS1* inhibitors. Relative levels of phospho-*EGFR* or *ALK* could predict the efficacy of targeted treatment in *EGFR*/*ALK* mutants in the study of Yang et al.[@b20-ott-10-3399] In the present study, all patients took *EGFR*-TKIs initially and eight took subsequent *ALK/ROS1* inhibitor. The median value of PFS was 6.6 months for 13 patients on *EGFR*-TKIs. However, among eight patients on crizotinib, six obtained disease control. Owing to efficacy difference for dosing order of targeted therapy, despite a low frequency, there is a future need of using a useful marker for selecting targeted treatment in patients with concomitant genes. Except at the level of phosphorylation, abundance of gene was identified previously as a predictor of targeted therapy;[@b21-ott-10-3399] the abundance level of different genes in one sample should be detected for patients with concomitant genes.

A small sample size was a major drawback of the present study. Second, not all patients received crizotinib after ineffective *EGFR*-TKIs. As a result, the clinical efficacy of further treatment could not be fully evaluated. Third, only RT-PCR was used for *ALK/ROS1* genes so that false positives might ensue. Moreover, RT-PCR could not provide convincing evidence for the dominance of expression for one oncogene aberration over another in the same samples. In addition, it was impossible to check whether individual tumor cells had these two mutations simultaneously or singly.[@b22-ott-10-3399] However, our findings are meaningful for clinical practice.

Conclusion
==========

A total of 3.1% of *EGFR*-mutated patients harbored *ALK/ROS1* fusion genes. Concomitant genes of *ALK/ROS1* might decrease the therapeutic efficacy of *EGFR*-TKIs.

Supplementary material
======================

###### 

The subtypes of *EGFR/ALK/ROS1* genes

  Gene type         Subtype of gene
  ----------------- ---------------------------------------
  *ALK* fusion      *EML4* exon 13; *ALK* exon 20
                    *EML4* exon 6 ins 33; *ALK* exon 20
                    *EML4* exon 20; *ALK* exon 20
                    *EML4* exon 18; *ALK* exon 20
                    *EML4* exon 2; *ALK* exon 20
  *ROS1* fusion     *SLC34A2* exon 4; *ROS1* exon 32
                    *SLC34A2* exon 14 del; *ROS1* exon 32
                    *CD74* exon 6; *ROS1* exon 32
                    *SDC4* exon 2; *ROS1* exon 32
                    *SDC4* exon 4; *ROS1* exon 32
                    *SLC34A2* exon 4; *ROS1* exon 34
                    *SLC34A2* exon 14 del; *ROS1* exon 34
                    *CD74* exon 6; *ROS1* exon 34
                    *SDC4* exon 4; *ROS1* exon 34
                    *EZR* exon 10; *ROS1* exon 34
                    *TPM3* exon 8; *ROS1* exon 35
                    *LRIG3* exon 16; *ROS1* exon 35
                    *GOPC* exon 8; *ROS1* exon 35
                    E746_A750del (1)
                    E746_A750del (2)
                    L747_P753\>S
                    E746_T751\>I
                    E746_T751del
                    E746_S752\>V
                    L747_T751\>Q
                    L747_E749del
                    L747_S752del
                    L747_A750\>P
  *EGFR* mutation   L747_P753\>Q
                    L747_T751del
                    L747_T751\>P
                    S768I
                    L858R
                    G719A
                    G719C
                    G719S
                    T790M
                    L861Q
                    H773_V774insH
                    D770_N771insG
                    V769_D770insASV
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###### 

Characteristics of the study population and comparison (n=421)

  Characteristics                             Total   Single EGFR mutation (n=408)   Concurrent gene (n=13)   *P*-value
  ------------------------------------------- ------- ------------------------------ ------------------------ -----------
  Gender                                                                                                      0.37
   Male                                       245     239                            6                        
   Female                                     176     169                            7                        
  Age, years                                                                                                  0.04
   \<60                                       224     213                            11                       
   ≥60                                        197     195                            2                        
  Smoking status                                                                                              0.20
   Never                                      305     295                            12                       
   Former/current                             116     113                            1                        
  Stage at *EGFR*-TKI treatment                                                                               0.83
   IIIB                                       12      12                             0                        
   IV                                         409     396                            13                       
  *EGFR* mutation type                                                                                        0.67
   Exon 19 deletion + exon 21 L858R           386     374                            12                       
   Other types                                35      34                             1                        
  Performance score at *EGFR*-TKI treatment                                                                   0.70
   0--1                                       356     345                            11                       
   2--3                                       65      63                             2                        

**Abbreviation:** TKI, tyrosine kinase inhibitor.

###### 

Clinical characteristics of 13 patients with EGFR and ALK/ROS1 concurrent genes

  Case   Gender   Age (years)   Smoking history   EGFR type   EGFR-TKI PFS   Response   *ALK*/ROS1     Crizotinib PFS   Response   Post-TKI treatment   Response   OS/month
  ------ -------- ------------- ----------------- ----------- -------------- ---------- -------------- ---------------- ---------- -------------------- ---------- ----------
  1      Female   47            No                19del       6.6            PR         EML4--*ALK*    --               --         Chemotherapy         SD         23.0
  2      Male     55            No                G719X       2.0            PD         EML4--*ALK*    11.2             PR         Supportive care      --         21.0
  3      Female   57            No                19del       3.1            SD         EML4--*ALK*    6.0              PR         Supportive care      --         11.5
  4      Male     59            No                L858R       4.0            SD         EML4--*ALK*    5.0              SD         Chemotherapy         PR         45.0
  5      Female   65            No                19del       17.5           PR         EML4--*ALK*    --               --         Supportive care      --         23.5
  6      Female   62            No                L858R       12.0           PR         EML4--*ALK*    --               --         Chemotherapy         PD         33.2
  7      Male     56            Yes               19del       10.2           PR         EML4--*ALK*    --               --         Supportive care      --         24.0
  8      Female   55            No                19del       1.1            PD         CD74--*ROS1*   7.0              SD         Chemotherapy         PD         15.4
  9      Male     45            No                19del       2.0            PD         EZR--*ROS1*    23.0             PR         Chemotherapy         PD         35.0
  10     Female   49            No                L858R       1.3            PD         EML4--*ALK*    --               --         Supportive care      --         17.6
  11     Female   38            No                19del       9.0            PR         EML4--*ALK*    1.2              PD         Chemotherapy         SD         21.5
  12     Male     59            No                L858R       7.6            PR         CD74--*ROS1*   2.0              PD         Chemotherapy         PD         24
  13     Male     51            No                19del       8.2            SD         EML4--*ALK*    7.5              PR         Chemotherapy         SD         48+

**Abbreviations:** TKI, tyrosine kinase inhibitor; PFS, progression-free survival; OS, overall survival; PR, partial response; SD, stable disease; PD, progressive disease.

###### 

Clinical efficacy comparison of *EGFR*-TKI in single *EGFR* mutation and concurrent gene alterations

  Best response   Single EGFR mutation (n=408)   Concurrent gene (n=13)   *P*-value
  --------------- ------------------------------ ------------------------ -----------
  CR, n (%)       2 (0.5)                        0 (0.0)                  --
  PR, n (%)       249 (61.0)                     6 (46.2)                 --
  SD, n (%)       87 (21.3)                      3 (23.1)                 --
  PD, n (%)       70 (17.2)                      4 (30.8)                 --
  ORR (%)         61.5                           46.2                     0.26
  DCR (%)         82.8                           69.2                     0.37
  Median PFS      10.7                           6.6                      0.004
  Median OS       21.0                           23.0                     0.196

**Abbreviations:** TKI, tyrosine kinase inhibitor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival.
